FindTrial
Sign In

Chemokine Receptor 4–Targeted 68Ga-Pentixafor PET/CT in differentiated thyroid cancer

Chemokine Receptor 4–Targeted 68Ga-Pentixafor PET/CT in differentiated thyroid cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084339
Enrollment
Unknown
Registered
2024-05-14
Start date
2023-09-14
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemokine Receptor 4–Targeted 68Ga-Pentixafor PET/CT in differentiated thyroid cancer

Interventions

Gold Standard:18F-FDG PET/CT
Index test:68Ga-Pentixafor PET/CT

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients pathologically confirmed as DTC, and who previously received total/near-total thyroidectomy and 131I treatment; 2. Patients with Tg= 10 ng/mL under TSH stimulation, iodine absorption rate =1%, and treatment dose 131I imaging without abnormal iodine uptake lesions

Exclusion criteria

Exclusion criteria: 1. Patients during pregnancy or lactation; 2. Patients complicated with other malignant tumors; 3. Patients who can not sign the scanned informed consent.

Design outcomes

Primary

MeasureTime frame
Sensitivity;Accuracy;Negative predicative value;Specificity;—

Secondary

MeasureTime frame
Positive predicative value;—

Countries

China

Contacts

Public ContactRui Huang

West China Hospital of Sichuan University

huang_rui@scu.edu.cn+86 189 8060 5781

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026